David M Waterhouse
Overview
Explore the profile of David M Waterhouse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sultan I, Waterhouse D, Chopra D, Lonshteyn A, Weycker D, Delea T, et al.
Adv Ther
. 2024 Oct;
41(12):4648-4659.
PMID: 39470877
Introduction: Sotorasib was the first drug approved for adults with Kirsten rat sarcoma G12C-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) who received prior systemic therapy in the US. This...
2.
Kirkwood M, Schenkel C, Hinshaw D, Bruinooge S, Waterhouse D, Peppercorn J, et al.
JCO Oncol Pract
. 2024 Oct;
21(3):427-437.
PMID: 39356976
Purpose: In this study, we describe the geographic distribution of US cancer treatment trials to identify disparities and opportunities for targeted improvements in access to research for people with cancer....
3.
Waterhouse D, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, et al.
Lung Cancer
. 2024 Sep;
196:107921.
PMID: 39303400
Background: In the CodeBreaK 200 phase III, open-label trial, sotorasib significantly improved efficacy versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) for...
4.
Harvey R, Miller T, Hurley P, Thota R, Black L, Bruinooge S, et al.
Cancer
. 2024 Jan;
130(8):1193-1203.
PMID: 38193828
No abstract available.
5.
Waterhouse D, Ward P, Drosick D, Burdette C, Davies D, Mendenhall M
JCO Oncol Pract
. 2023 Sep;
19(11):1053-1057.
PMID: 37738533
Purpose: Biosimilars are clinically equivalent to branded products yet cost significantly less. Interchangeability is a US Food and Drug Administration (FDA) designation that allows generic drugs to be substituted for...
6.
Mendenhall M, Guinigundo A, Davies D, Ward P, Drosick D, Waterhouse D
JCO Oncol Pract
. 2023 Jun;
20(2):262-267.
PMID: 37369093
Purpose: Despite data-driven consensus recommendations, there remains significant nonadherence to genetic screening and testing. More than 300,000 patients are diagnosed with breast cancer annually, with one third of these estimated...
7.
Waterhouse D, Ward P, Arnal S, Neubauer M, Drosick D, Davies D, et al.
JCO Oncol Pract
. 2023 May;
19(6):e951-e956.
PMID: 37126768
Purpose: Non-small-cell lung cancer (NSCLC), the leading cause of cancer death in the United States, accounts for 85% of all lung cancer cases. Biomarker testing is an integral part of...
8.
He K, Berz D, Gadgeel S, Iams W, Bruno D, Blakely C, et al.
J Thorac Oncol
. 2023 Feb;
18(7):907-921.
PMID: 36842467
Introduction: Sitravatinib, a receptor tyrosine kinase inhibitor targeting TYRO3, AXL, MERTK receptors, and vascular epithelial growth factor receptor 2, can shift the tumor microenvironment toward an immunostimulatory state. Combining sitravatinib...
9.
Guo M, Marrone K, Spira A, Waterhouse D, Scott S
Onco Targets Ther
. 2021 Dec;
14:5321-5331.
PMID: 34853516
dysregulation promoting tumorigenesis in non-small cell lung cancer (NSCLC) is associated with worse outcomes following chemotherapy as compared to non-driver mutated NSCLC and occurs either through mutations causing exon 14...
10.
Waterhouse D, Tseng W, Espirito J, Robert N
Clin Lung Cancer
. 2021 Jun;
22(6):e901-e910.
PMID: 34187757
Introduction: Although guidelines recommend testing for actionable biomarkers for patients with advanced or metastatic non-small cell lung cancer (NSCLC), testing rates have varied. This study aimed to assess molecular testing...